Search clinical trials for: Doravirine

Total 115 results

University of Colorado, Denver
Gilead Sciences

Completed

Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance

Weight Gain | HIV-1-infection

United States
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Recruiting

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

HIV Infections | Pregnancy Related

United States
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
Gamaleya Research Institute of Epidemiology and...
MSD Pharmaceuticals LLC

Not yet recruiting

HIV A6 Genome In ART Unsuccessful Patients On DOR (HIV-A6-DOR)

Virus-HIV
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
University of Roma La Sapienza

Recruiting

Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge). (DORAge)

HIV

Italy
Clinique du Quartier Latin
Merck Frosst Canada Ltd.

Unknown

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

HIV Infections

Canada, Martinique
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Merck Sharp & Dohme LLC

Completed

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

HIV-infected Participants With ESRD Undergoing Routine Hemodialysis

Spain
Chelsea and Westminster NHS Foundation Trust
Merck Sharp & Dohme LLC; Imperial College London; University of Liverpool

Completed

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

Human Immunodeficiency Virus

United Kingdom
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Fundacion Clinic per a la Recerca Biomedica

Active, not recruiting

Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

HIV-1-infection

Spain
Merck Sharp & Dohme LLC

Completed

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

HIV-1 Infection
Braintree Laboratories

Completed

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

Constipation

United States
Merck Sharp & Dohme LLC

Recruiting

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection

United States, Mexico, Russian Federation, South Africa, Thailand
Institut de Médecine et d'Epidémiologie Appliquée...
Merck Sharp & Dohme LLC

Active, not recruiting

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" (DORASPEP)

HIV Infections

France
Merck Sharp & Dohme LLC

Completed

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

HIV-1 | Central Nervous System
IRCCS Eugenio Medea
University of Rome Tor Vergata

Completed

Safety and Efficacy of Etravirine in Friedreich Ataxia Patients (FAEST1)

Friedreich Ataxia

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

HIV Infections

United States, Brazil, South Africa
Tibotec Pharmaceuticals, Ireland

Completed

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

HIV-Infections
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
University of Colorado, Denver

Completed

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

Hepatitis C | HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

HIV Infections

United States, South Africa, Thailand
Centre de Recherches et d'Etude sur la Pathologie...

Active, not recruiting

Adipose Tissue After Switch to Doravirine (ADDORE)

HIV Infections

France
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Lee's Pharmaceutical Limited

Unknown

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Acquired Thrombotic Thrombocytopenic Purpura

China
University of Southern California
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

HIV

United States
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects

Bacterial Infections

United States
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Germans Trias i Pujol Hospital

Completed

Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

HIV

Spain
University of Liverpool
Liverpool School of Tropical Medicine; Desmond Tutu Health Foundation

Recruiting

Doravirine Dose Optimisation in Pregnancy (DoraDO)

HIV

South Africa
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Hepatitis B | Hepatitis C, Chronic | Human Immunodeficiency Virus

United States, Canada, Poland
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (DRIVE-SHIFT)

HIV-1 Infection
Chelsea and Westminster NHS Foundation Trust

Recruiting

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)

HIV-1-infection

United Kingdom
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

HIV-1 Infection

United States, Italy, Russian Federation, South Africa, Thailand
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
University of North Carolina, Chapel Hill
Janssen Pharmaceuticals

Completed

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

HIV Infections

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

HIV Infection

United States, Russian Federation, Argentina, Australia, Canada, Chile, Colombia, Israel, Japan, New Zealand, Puerto Rico, South Africa, Switzerland, Taiwan, United Kingdom
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

AML | Refractory | Relapsed

China
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Human Immunodeficiency Virus (HIV) Infection

France, Ukraine, United States, Mexico, Romania, South Africa, Peru, Argentina, Puerto Rico, Russian Federation, Guatemala
Merck Sharp & Dohme LLC

Completed

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

HIV Infections
Professor Francois Venter

Recruiting

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance (ADORE)

HIV-1-infection

South Africa
University Hospital, Geneva
University Hospital, Basel, Switzerland; University of Lausanne Hospitals; University... and other collaborators

Completed

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz (SWITCH-EE)

Sleep Disorders

Switzerland
Merck Sharp & Dohme LLC

Completed

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

Human Immunodeficiency Virus (HIV) Infection
Professor Francois Venter

Completed

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (DORA)

HIV-1-infection

South Africa
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Institut d'Investigació Biomèdica de Bellvitge; Hospital Universitari de Bellvitge

Completed

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

HIV-1-infection

Spain
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.

HIV
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

HIV Infection
Janssen Sciences Ireland UC

Active, not recruiting

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

HIV Infections | HIV-1

United States, France, Spain, South Africa, Canada, Argentina, Thailand, Brazil, Romania, Panama, Puerto Rico

3

Subscribe